Cancer Therapy AdvisorIntensified ABVD Bests PET-Adapted ABVD as First-Line Therapy for Hodgkin Lymphoma

The FIL-ROUGE trial studied 503 adults with previously untreated Hodgkin lymphoma.

New research has provided evidence that intensified ABVD can enhance outcomes for patients with untreated Hodgkin lymphoma. The findings were presented at the International Conference on Malignant Lymphoma 2023 and contribute to ongoing discussions on optimal treatment regimens.

Key Points:

• Patients in the trial were treated with either dose-dense or dose-intense ABVD (ABVD_DD-DI) or PET-adapted ABVD.
• 3-year progression-free survival (PFS) and event-free survival (EFS) rates were 87% and 81% respectively for ABVD_DD-DI, compared to 73% and 67% respectively for PET-adapted ABVD.
• Complete response (CR) rate was higher with ABVD_DD-DI than with PET-adapted treatment at the end of the trial—94% versus 85%.
• Primary refractory disease rate was 4% in the ABVD_DD-DI arm and 12% in the PET-adapted treatment arm.

Additional Points:

• The 3-year overall survival rate was 99% in the ABVD_DD-DI arm and 98% in the PET-adapted treatment arm.
• Grade 3-4 adverse events occurred in 70% of ABVD_DD-DI patients and 57% of PET-adapted treatment patients.
• Serious adverse events were experienced by 25% of ABVD_DD-DI patients and 16% of PET-adapted treatment patients.

Conclusion:

• Intensified ABVD was found to improve PFS and EFS rates, and had a higher CR rate in the FIL-ROUGE trial. However, further data on mid-term and long-term toxicity are required.

Hematology/Oncology Latest Posts

• Major Lawsuit Against Cancer Charity Offers Reminder to OncologistsApril 29, 2024
• Oncology Fraud: Authorities Now Better Able to Detect Billing AbusesApril 29, 2024
• Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD ProphylaxisApril 29, 2024
• Oncology Leader Calls for Antitrust Probe: “We’re Talking About People’s Lives”April 15, 2024